


15. (twice amended) A polypharmacophore represented by formula (II):



(II)

wherein:

R₁ is -CO₂R₄, -CO₂N(R₄)₂, aryl, alkyl, aralkyl, or aralkenyl;



R₂ represents independently for each occurrence H, F, Cl, Br, I, amino, azido, nitro, sulfonate, sulfonyl, cyano, hydroxyl, alkyl, aryl, heteroalkyl, heteroaryl, aralkyl, trialkylsilyl, or acyl;

R₃ represents independently for each occurrence H, F, Cl, Br, I, amino, azido, nitro, sulfonate, sulfonyl, cyano, hydroxyl, alkyl, aryl, heteroalkyl, heteroaryl, aralkyl, trialkylsilyl, or acyl;

R₄ represents independently for each occurrence H, alkyl, aryl, alkenyl, alkynyl, heteroalkyl, or heteroaryl; and

the stereochemical configuration of the carbon-carbon double bond is *Z*, *E*, or a mixture of *Z* and *E*.

55. (new) The polypharmacophore of claim 15, wherein R₂ is F.
56. (new) The polypharmacophore of claim 15, wherein R₂ is F and R₃ is H.
57. (new) The polypharmacophore of claim 15, wherein R₁ is CO₂R₄.
58. (new) The polypharmacophore of claim 15, wherein R₁ is CO₂R₄ and R₄ is H.
59. (new) The polypharmacophore of claim 15, wherein said compound is selected from group consisting of:



60. (new) A pharmaceutical composition, comprising:

a polypharmacophore of claim 15, 55, 56, 57, 58 or 59, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.

32
final